Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease.

Animals Humans Mice alpha-Synuclein / genetics Disease Models, Animal Lewy Bodies Parkinson Disease / genetics Phosphorylation Protein Processing, Post-Translational
Parkinson’s disease acetylation alpha-synuclein nitration phosphorylation posttranslational modifications

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Aug 2023
Historique:
received: 01 08 2023
revised: 25 08 2023
accepted: 27 08 2023
medline: 11 9 2023
pubmed: 9 9 2023
entrez: 9 9 2023
Statut: epublish

Résumé

Parkinson's disease (PD) pathology is characterized by the loss of dopaminergic neurons of the nigrostriatal system and accumulation of Lewy bodies (LB) and Lewy neurites (LN), inclusions mainly composed of alpha-synuclein (α-Syn) fibrils. Studies linking the occurrence of mutations and multiplications of the α-Syn gene (

Identifiants

DOI: 10.3390/ijms241713435 PMID: 37686236 PMC: PMC10488235
pubmed: 37686236
pii: ijms241713435
doi: 10.3390/ijms241713435
pmc: PMC10488235
pii:
doi:

Substances chimiques

alpha-Synuclein 0
SNCA protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Michael J. Fox Foundation for Parkinson's Research, NY, USA
ID : #10742
Organisme : MSA Coalition, USA
ID : Testing MPH as a novel neuroprotective therapy in preclinical models of MSA
Organisme : MIUR PRIN
ID : 2017-1065
Organisme : Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
ID : EXC 2067/1- 390729940
Organisme : Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
ID : SFB1286 (B8)

Références

JAMA Neurol. 2020 Sep 28;:
pubmed: 32986090
Cell. 2003 Dec 12;115(6):727-38
pubmed: 14675537
Neuroscience. 2012 Jan 3;200:106-19
pubmed: 22079575
Nat Rev Neurol. 2010 Jun;6(6):309-17
pubmed: 20479780
Front Mol Neurosci. 2023 May 25;16:1197853
pubmed: 37305556
iScience. 2020 Mar 27;23(3):100910
pubmed: 32120069
Hum Mol Genet. 2020 Nov 4;29(18):3107-3121
pubmed: 32954426
Mov Disord. 2016 Oct;31(10):1535-1542
pubmed: 27548849
Ann N Y Acad Sci. 2003 Jun;991:1-14
pubmed: 12846969
J Neurosci. 2012 Jan 4;32(1):124-32
pubmed: 22219275
Sci Rep. 2020 Jan 14;10(1):204
pubmed: 31937832
Front Cell Neurosci. 2018 Apr 17;12:97
pubmed: 29719501
FEBS Lett. 2003 May 8;542(1-3):147-52
pubmed: 12729915
Sci Rep. 2019 Jul 29;9(1):10919
pubmed: 31358782
Front Neurosci. 2019 Apr 18;13:381
pubmed: 31057362
J Neurochem. 2016 Oct;139 Suppl 1:131-155
pubmed: 27018978
Mol Neurodegener. 2013 Nov 25;8:44
pubmed: 24267638
Int J Environ Res Public Health. 2020 Dec 29;18(1):
pubmed: 33383855
BMJ. 2004 Sep 11;329(7466):611-4
pubmed: 15361447
Sci Rep. 2017 Oct 20;7(1):13713
pubmed: 29057912
J Cell Biol. 2019 Jan 7;218(1):267-284
pubmed: 30538141
Biochim Biophys Acta. 2008 Oct;1783(10):1767-80
pubmed: 18634833
Front Neurol. 2021 Jul 15;12:661117
pubmed: 34335440
PLoS One. 2017 May 31;12(5):e0178576
pubmed: 28562630
J Biol Chem. 2000 Jun 16;275(24):18344-9
pubmed: 10747881
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8
pubmed: 12122208
Antioxidants (Basel). 2021 May 01;10(5):
pubmed: 34062880
Parkinsonism Relat Disord. 2013 Apr;19(4):407-15
pubmed: 23462481
Ann Neurol. 2023 Mar;93(3):446-459
pubmed: 36385395
PLoS One. 2014 Jul 30;9(7):e103727
pubmed: 25075858
J Biol Chem. 2008 Aug 22;283(34):23179-88
pubmed: 18562315
Front Synaptic Neurosci. 2020 Sep 11;12:586453
pubmed: 33041780
J Biol Chem. 2014 Feb 7;289(6):3652-65
pubmed: 24338013
J Neurosci Res. 2000 Jul 15;61(2):121-7
pubmed: 10878583
Neurosci Lett. 2017 Aug 10;655:90-94
pubmed: 28673834
Arch Neurol. 2008 Dec;65(12):1577-81
pubmed: 19064744
Neuropathol Appl Neurobiol. 1986 May-Jun;12(3):223-34
pubmed: 3016582
Mol Biol Cell. 2010 Jul 1;21(13):2128-37
pubmed: 20444973
Biochemistry. 2013 May 21;52(20):3436-45
pubmed: 23607618
Acta Neuropathol. 2018 Oct;136(4):621-639
pubmed: 30046897
J Proteome Res. 2019 May 3;18(5):2109-2120
pubmed: 30943367
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Science. 2007 Jul 27;317(5837):516-9
pubmed: 17588900
Science. 2000 Nov 3;290(5493):985-9
pubmed: 11062131
J Mol Biol. 2023 Jan 15;435(1):167825
pubmed: 36099961
Neurochem Res. 2011 Nov;36(11):2029-42
pubmed: 21674238
Nat Neurosci. 2023 Feb;26(2):213-225
pubmed: 36690898
Mol Neurodegener. 2016 Jan 19;11:7
pubmed: 26782965
Sci Rep. 2014 Jul 23;4:5797
pubmed: 25052239
J Neurosci. 2002 Apr 1;22(7):2780-91
pubmed: 11923443
Biochemistry. 2012 Jun 26;51(25):5004-13
pubmed: 22694188
Mol Neurobiol. 2019 Apr;56(4):2466-2481
pubmed: 30032424
Neurobiol Dis. 2012 Mar;45(3):939-53
pubmed: 22182688
Brain. 2017 May 1;140(5):1399-1419
pubmed: 28398476
ACS Chem Neurosci. 2017 Oct 18;8(10):2145-2151
pubmed: 28741930
J Biol Chem. 2004 Nov 12;279(46):47746-53
pubmed: 15364911
Biochemistry. 2022 Sep 6;61(17):1743-1756
pubmed: 35944093
EMBO J. 2007 Jul 11;26(13):3169-79
pubmed: 17581637
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11332-6
pubmed: 8248248
Neuropathol Appl Neurobiol. 2016 Feb;42(1):77-94
pubmed: 26613567
Acta Neuropathol. 2013 Dec;126(6):793-807
pubmed: 23912309
Int J Mol Sci. 2020 Sep 29;21(19):
pubmed: 33003340
Acta Neuropathol Commun. 2022 Jul 6;10(1):98
pubmed: 35794636
Acta Neuropathol. 2010 Jun;119(6):703-13
pubmed: 20229352
Nature. 2011 Aug 14;477(7362):107-10
pubmed: 21841800
Parkinsonism Relat Disord. 2019 Jun;63:143-148
pubmed: 30796010
Brain Res. 2012 Oct 2;1476:183-202
pubmed: 22560500
CRC Crit Rev Biochem. 1985;18(4):281-325
pubmed: 3902358
Protein Sci. 2012 Jul;21(7):911-7
pubmed: 22573613
J Am Chem Soc. 2011 May 11;133(18):7152-8
pubmed: 21491910
Sci Rep. 2017 Nov 28;7(1):16533
pubmed: 29184069
J Parkinsons Dis. 2019;9(3):501-515
pubmed: 31282427
NPJ Parkinsons Dis. 2023 Jan 16;9(1):4
pubmed: 36646701
Mov Disord. 2023 Jan;38(1):153-155
pubmed: 36259554
J Neurosci. 2005 Jun 8;25(23):5544-52
pubmed: 15944382
Int Rev Cell Mol Biol. 2015;316:267-305
pubmed: 25805127
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2109617119
pubmed: 35353605
Sci Rep. 2013;3:2540
pubmed: 23985836
BMC Proc. 2009 Aug 04;3 Suppl 6:S1
pubmed: 19660094
J Am Chem Soc. 2015 Apr 22;137(15):5041-52
pubmed: 25768729
PLoS Biol. 2017 Mar 3;15(3):e2000374
pubmed: 28257421
Prog Brain Res. 2010;183:115-45
pubmed: 20696318
Antioxid Redox Signal. 2013 Sep 20;19(9):912-8
pubmed: 23418747
FEBS Lett. 2004 Aug 13;572(1-3):227-32
pubmed: 15304353
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
J Biol Chem. 2012 Aug 17;287(34):28243-62
pubmed: 22718772
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3213-9
pubmed: 22315428
J Biol Chem. 2006 Oct 6;281(40):29739-52
pubmed: 16847063

Auteurs

Viviana Brembati (V)

Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.

Gaia Faustini (G)

Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
ORCID: 0000-0002-0751-3082

Francesca Longhena (F)

Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
ORCID: 0000-0001-6569-9412

Tiago Fleming Outeiro (TF)

Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Goettingen, 37073 Goettingen, Germany.
Max Planck Institute for Multidisciplinary Sciences, 37075 Goettingen, Germany.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK.
ORCID: 0000-0003-1679-1727

Arianna Bellucci (A)

Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
ORCID: 0000-0002-9581-1919

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines associées à la maladie de Parkinson › alpha-Synucléine › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Cellules › Structures cellulaires › Corps d'inclusion › Corps de Lewy › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Métabolisme › Phosphorylation › Changes in α-Synuclein Posttranslational...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Modification traductionnelle des protéines › Maturation post-traductionnelle des protéines › Changes in α-Synuclein Posttranslational...